Płońska Edyta, Krzyzanowska-Swiniarska Barbara, Gruszczyńska Mirosława, Pynka Sławomir, Lewandowski Maciej, Kornacewicz-Jach Zdzisława, Pilarska Krystyna
Pomorska Akademia Medyczna w Szczecinie, Klinika Kardiologii.
Pol Merkur Lekarski. 2006 Apr;20(118):386-9.
The aim of the study was to analyze the functional and structural changes in the echocardiographic parameters of the left ventricle (LV) in adult patients (pts) with growth hormone deficiency (GHD) without any treatment in childhood before and after one year long somatropin treatment.
Twelve GHD pts (mean age 42 +/- 10 years; M/F: 6/6) before (group GHD-1) and after one year rhGH therapy (group GHD-2) were compared. The s.c. rhGH treatment with somatropin (Genotropin, Pharmacia) at a dose 0.125 U/kg/week up to 0.25 U/kg/week has been continued for 1 year. Both groups were examined with echocardiography Twelve GHD pts (mean age 42 +/- 10 years; M/F: 6/6): with indiopatic GHD (n = 10, age from 29 to 46 years; M/F: 6/4) and with Sheehan syndrome (n = 2, age from 46 to 61 years; M/F: 0/2) before (group GHD-1) and after one year rhGH therapy (group GHD-2) were compared. The s.c. rhGH treatment with somatropin (Genotropin, Pharmacia) at a dose 0.125 U/kg/week up to 0.25 U/kg/week (till 50 percentyl of blood IGF-1 concentration for age and sex norm ) has been continued for 1 year. Both groups were examined with echocardiography.
On echocardiography, in the group GHD-1 pts compared to GHD-2 pts, had lower LVM and LVMI were lower (adequately (138.4 +/- 39.8 vs. 153.1 +/- 49.5, p < 0.036), lower and LVMI (87.3 +/- 19.7 vs. 96 +/- 23.7, p < 0.05). There was no Therapy had no significant therapy effect on systolic LV function. The diastolic function of LV did not differ between both GHD-1 and GHD-2 groups (E/A: 1.4 +/- 0.2 vs. 1.3 +/- 0.3 ; E: 79 +/- 17; A: 59 +/- 16 vs. 58 +/- 10, ns), but DT increased significantly from 132 +/- 21 vs. 147 +/- 30, p < 0.05). There was only significant correlation between LV systolic dimension after one year and IGF plasma basal concentration (r = 0.7, p < 0.01).
One year medical therapy with rhGH (somatropin) is associated with a significant positive effect on LVM and LVMI but no significant effect on systolic LV function, as assessed by echocardiography in adults with GHD. Significant decrease of DT after therapy may suggest an influence of GH therapy on diastolic LV function. The level of IGF did correlate with LV systolic diameter after therapy.
本研究的目的是分析成年生长激素缺乏症(GHD)患者在未接受任何治疗的儿童期之前以及接受一年生长激素治疗之后,左心室(LV)超声心动图参数的功能和结构变化。
比较了12例GHD患者(平均年龄42±10岁;男/女:6/6)在治疗前(GHD - 1组)和接受一年重组人生长激素(rhGH)治疗后(GHD - 2组)的情况。采用生长激素(健高灵,法玛西亚公司)皮下注射治疗,剂量从0.125 U/kg/周逐渐增加至0.25 U/kg/周,持续治疗1年。两组均接受超声心动图检查。12例GHD患者(平均年龄42±10岁;男/女:6/6):特发性GHD患者(n = 10,年龄29至46岁;男/女:6/4)和希恩综合征患者(n = 2,年龄46至61岁;男/女:0/2),比较其治疗前(GHD - 1组)和接受一年rhGH治疗后(GHD - 2组)的情况。采用生长激素(健高灵,法玛西亚公司)皮下注射治疗(剂量从0.125 U/kg/周逐渐增加至0.25 U/kg/周,直至达到年龄和性别标准的血液IGF - 1浓度的50百分位数),持续治疗1年。两组均接受超声心动图检查。
超声心动图显示GHD - 1组患者与GHD - 2组患者相比,左心室质量(LVM)和左心室质量指数(LVMI)较低(分别为138.4±39.8与153.1±49.5,p < 0.036),LVMI也较低(87.3±19.7与96±23.7,p < 0.05)。治疗对左心室收缩功能无显著影响。GHD - 1组和GHD - 2组左心室舒张功能无差异(E/A:1.4±0.2与1.3±0.3;E:79±17;A:59±16与58±10,无显著差异),但舒张期时间(DT)从132±21显著增加至147±30,p < 0.05)。仅治疗一年后的左心室收缩内径与基础血浆IGF浓度之间存在显著相关性(r = 0.7,p < 0.01)。
通过超声心动图评估,对于成年GHD患者,一年的rhGH(生长激素)药物治疗对LVM和LVMI有显著的积极影响,但对左心室收缩功能无显著影响。治疗后DT显著降低可能提示生长激素治疗对左心室舒张功能有影响。治疗后IGF水平与左心室收缩直径相关。